Kyle Rhodes, MD
Ophthalmology · Lakeway, TXNPI 1821272378
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,332 of the $50,121 with a category attached, or 86.5%. Rxsight Inc accounts for 87.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $43,087 and has fallen 96.4% since, to $1,561 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $187.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$44K
- Johnson & Johnson Surgical Vision, Inc.$3K
- AbbVie$1K
- Alcon$829
- Sun Pharmaceutical Industries Inc.$398
- Ocular Therapeutix, Inc.$305
- plus $833 from 13 others
Across 90 payments — averaging $8496.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$289K
- Oyster Point Pharma, Inc.$174K
- Novartis$166K
- Ocular Therapeutix, Inc.$75K
- Kala Pharmaceuticals, Inc.$49K
- AbbVie$7K
- plus $5K from 3 others
What the payments were for
- Consulting fees$43,33286%
- Speaking & faculty fees$260%
- Food & beverage$6,70113%
- Education$180%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 36 | $43,697 |
| Johnson & Johnson Surgical Vision, Inc. | 77 | $2,698 |
| AbbVie(2 entities) | 63 | $1,362 |
| Alcon | 26 | $829 |
| Sun Pharmaceutical Industries Inc. | 21 | $398 |
| Ocular Therapeutix, Inc. | 14 | $305 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $191 |
| Bausch & Lomb Americas Inc. | 7 | $128 |
| Kowa Research Institute, Inc. | 1 | $89 |
| Ivantis, Inc | 2 | $80 |
| Biotissue Holdings Inc. | 4 | $75 |
| Glaukos Corporation | 2 | $52 |
| Carl Zeiss Meditec, Inc. | 1 | $52 |
| Tearlab Corp | 1 | $41 |
| Eyepoint US, Inc. | 1 | $34 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Sight Sciences, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$42,000
- RXSIGHT CONTACT LENS$750
- RXSIGHT INJECTOR CARTRIDGE$750
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$750
- LIGHT ADJUSTABLE LENS (LAL)$750
- RXSIGHT INJECTOR HANDPIECE$750
- Tecnis Symfony IOL$532
- Centurion$137
- CATALYS SYSTEM$122
- One Series Ultra$112
- Catalys Laser System$112
- Whitestar Phacoemulsficiation System$112
- Tecnis Simplicity$111
- Tecnis IOL$110
- STELLARIS$107
- Clareon$102
- Tecnis Multifocal Family of 1-piece IOLS$101
How this compares
$50,122 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 71 | $54,830 |
| LumiganBimatoprost | 79 | $33,455 |
| Cyclosporine | 43 | $18,833 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,464 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $13,423 |
| VyzultaLatanoprostene Bunod | 18 | $10,190 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $6,888 |
| Brinzolamide | 23 | $5,520 |
| Alphagan PBrimonidine Tartrate | 13 | $4,947 |
| Travoprost | 19 | $4,476 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $3,818 |
| Latanoprost | 339 | $3,242 |
| Prednisolone Acetate | 105 | $2,989 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 112 | $2,714 |
| Loteprednol Etabonate | 13 | $2,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,362 | $106,655200 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $128 | $23,65436 claims |
| AlconSimbrinza | $829 | $3,81821 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $191 | $2,09813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Lakeway
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.